endothelin-1 and Cushing-Syndrome

endothelin-1 has been researched along with Cushing-Syndrome* in 2 studies

Trials

1 trial(s) available for endothelin-1 and Cushing-Syndrome

ArticleYear
Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome.
    European journal of endocrinology, 2003, Volume: 149, Issue:6

    Recently the pathophysiological role of endothelin (ET) has been presumed in a number of adrenal disorders such as primary hyperaldosteronism, pheochromocytoma and adrenocortical insufficiency.. The aim of the present study was to evaluate circulating ET-1 levels in patients with endogenous Cushing's syndrome.. Plasma ET-1 levels were determined by highly sensitive RIA. Thirteen untreated subjects with Cushing's syndrome were studied: eight women and five men of mean age 44.2+/-9.5 Years (s.d.). In ten of them, Cushing's disease had been diagnosed and three had adrenal adenomas. ET-1 was 3-fold higher in the patient group than in age-matched healthy controls (n=13): 1.59+/-0.78 vs 0.46+/-0.20 pmol/l respectively, P<0.001. In adrenal adenoma patients, ET-1 was not significantly higher than in the Cushing's disease subjects (1.84+/-0.67 vs 1.51+/-0.83 pmol/l respectively, P>0.05). In three patients who died of severe cardiovascular complications, plasma ET-1 was significantly higher than in the remaining patients (2.34+/-0.35 pmol/l, P<0.05). A positive correlation was found between the total cholesterol (6.94+/-1.75 mmol/l) and ET-1 levels in the patients with Cushing's syndrome: r=+0.73, P<0.02. No correlation was observed, however, between the levels of ET-1 and blood pressure (183+/-37/106+/-18 mmHg), plasma cortisol levels (455.2+/-74.5 nmol/l) or urinary cortisol excretion (1463+/-726 nmol/24 h). The successful treatment and correction of hypercortisolism in seven patients led to insignificant reduction in plasma ET from 1.34+/-0.69 to 0.73+/-0.53 pmol/l, P>0.05.. Our results clearly demonstrate that the ET system is activated in Cushing's syndrome. Elevated plasma ET-1 levels probably play a role in the pathogenesis of accelerated and early atherosclerosis development in this disorder.

    Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Cardiovascular Diseases; Cushing Syndrome; Endothelin-1; Female; Humans; Hydrocortisone; Male; Matched-Pair Analysis; Middle Aged; Reference Values; Risk Factors

2003

Other Studies

1 other study(ies) available for endothelin-1 and Cushing-Syndrome

ArticleYear
Expression of endothelin-1 by adrenocortical carcinoma: a new target for anti-cancer therapy?
    Acta chirurgica Belgica, 2004, Volume: 104, Issue:5

    Adrenocortical carcinoma is a rare neoplasm with poor prognosis. Endothelin-1 (ET-1) has been implicated in carcinogenesis, but has never been studied in this neoplasm. A 76-year-old woman with Cushing's syndrome due adrenocortical carcinoma was operated on and the tumour removed was studied by immunohistochemistry for ET-1. Patient history illustrates the poor prognosis of this cancer that became metastatic after one year. Immunohistochemical studies disclosed a strong expression of ET-1 by adrenocortical carcinoma cells. As shown in other cancers, ET-1 expression by adrenocortical carcinoma may suggest a pathogenic role of ET-1 in tumorigenesis that possibly could be countered by ET-1 receptor antagonists. These agents could open new therapeutic perspectives to treat a carcinoma known to have a poor prognosis.

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Cushing Syndrome; Endothelin-1; Female; Humans; Immunohistochemistry

2004